As the population ages, the incidence of patients presenting for surgical procedures with diastolic dysfunction and heart failure with preserved ejection fraction will rise. This review will discuss the most current and relevant information on the pathophysiology, treatment, and perioperative management of these patients.
AurigemmaGPZileMRGaaschWH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation. 2006;113:286-304.
2.
DicksteinKCohen-SolalAFilippatosG. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2008;29:2388-2442.
3.
HalleyCMHoughtalingPLKhalilMKThomasJDJaberWA. Mortality rate in patients with diastolic dysfunction and normal systolic dysfunction. Arch Intern Med. 2011;171:1082-1087.
4.
McGradyMReidCMShielL. N-terminal B-type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the screening evaluation of the evolution of new heart failure study. Eur J Heart Fail. 2013;15:573-580.
5.
KaneGCKaronBLMahoneyDW. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306:856-863.
6.
KuznetsovaTHerbotsLLopezB. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail. 2009;2:105-112.
7.
OwanTERedfieldMM. Epidemiology of chronic heart failure. Prog Cardiovasc Dis. 2005;47:320-332.
8.
OwanTEHodgeDOHergesRMJacobsenSJRogerVLRedfieldMM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
9.
SharpATappRFrancisDP. Ethnicity and left ventricular diastolic dysfunction in hypertension: an ASCOT substudy. J Am Coll Cardiol. 2008;52:1015-1021.
10.
SatpathyCMishraTKSatpathyRSatpathyHKBaroneE. Diagnosis and management of diastolic dysfunction and heart failure. Am Fam Physician. 2006;73:841-846.
11.
NewtonJBBlackledgeHMSquireIB. Ethnicity and variation in prognosis for patients newly hospitalized for heart failure. Heart. 2003;91:1545-1550.
12.
ThomasJDPopovicZB. Assessment of left ventricular function by cardiac ultrasound. J Am Coll Cardiol. 2006;48:2012-2025.
13.
SenguptaPPKhandheriaBKNarulaJ. Twist and untwist mechanics of the left ventricle. Heart Fail Clin. 2008;4:315-324.
14.
OkiTTabataTYamadaH. Clinical application of pulsed Doppler tissue imaging for assessing abnormal left ventricular relaxation. Am J Cardiol. 1997;70:921-928.
15.
OmmenSNishimuraRAAppletonCP. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures. Circulation. 2000;102:1788-1794.
16.
LittleWOhJK. Echocardiographic evaluation of diastolic function can be used to guide clinical care. Circulation. 2009;120:802-809.
17.
HaJWOhJKRedfieldMMUjinoKSewardJBTajikAJ. Triphasic mitral inflow velocity with mid-diastolic filling; clinical applications and associated echocardiographic findings. J Am Soc Echocardiogr. 2004;17:428-431.
18.
LamCSHanLHaJWOhJKLingLH. The mitral L wave: a marker of pseudonormal filling and predictor of heart failure in patients with left ventricular hypertrophy. J Am Soc Echocardiogr. 2005;18:336-341.
19.
OhJKParkSJNaguehSF. Established and novel clinical applications of diastolic function assessment by echocardiography. Circ Cardiovasc Imaging. 2011;4:444-455.
20.
ZileMRBrutsaertDL. New concepts of diastolic dysfunction and diastolic heart failure: diagnosis, prognosis and measurement of diastolic function. Circulation. 2002;105:1387-1393.
21.
KitzmanDWLittleWCBrubakerPH. Pathophysiological characteristics of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144-2150.
22.
WangJKurrelmeyerKMTorre-AmioneGNaguehSF. Systolic and diastolic dyssynchrony in patients with diastolic heart failure and the effect of medical therapy. J Am Coll Cardiol. 2007;49:88-96.
23.
LamCSRogerVLRodehefferRJ. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted county, Minnesota. Circulation. 2007;115:1982-1990.
24.
BourlaugBAKassDA. Ventricular-vascular interaction in heart failure. Heart Fail Clin. 2008;4:23-36.
25.
KawaguchiMHayIFeticsBKassDA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714-720.
26.
OrsoFBaldasseroniSMaggioniAP. Heart rate in coronary syndromes and heart failure. Prog Cardiovasc Dis. 2009;32:38-43.
27.
NeefSMaierLS. Remodeling of excitation-contraction coupling in the heart: inhibition of sarcoplasmic reticulum (Ca2+) leak as a novel therapeutic approach. Curr Heart Fail Rep. 2007;4:11-17.
28.
MattiazziAKraniasEG. CaMKII regulation of phospholamban and SR Ca2+ load. Heart Rhythm. 2011;8:784-787.
29.
McCauleyMDWehrensXH. Ryanodine receptor phosphorylation, calcium/calmodulin-dependent protein kinase II and life-threatening ventricular arrhythmias. Trends Cardiovasc Med. 2011;21(2):48-51.
30.
WitcherDRKovacsRJSchulmanHCefaliDCJonesLR. Unique phosphorylation site on the cardiac ryanodine receptor regulates calcium channel activity. J Biol Chem. 1991;266:11144-11152.
BorbelyAFalcao-PiresIvan HeerebeekL. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res. 2009;104:780-786.
33.
RoeNDRenJ. Oxidative activation of Ca2+/calmodulin-activated kinase II mediates ER stress-induced cardiac dysfunction and apoptosis. Am J Physiol Heart Circ Physiol. 2013;36:H828-H839.
34.
BorberlyAvan der VeldenJPappZ. Cardiomyocyte stiffness in diastolic heart failure. Circulation. 2005;111:774-781.
35.
PaulusWJBronzwaerJG. Nitric oxide’s role in the heart: control of beating or breathing?Am J Physiol Heart Circ Physiol. 2004;287:H8-H13.
36.
TakimotoEBelardiDTocchettiCG. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phophodiesterase type 5. Circulation. 2007;115:2159-2167.
37.
van HeerebeekLFranssenCPHamdaniNVerheugtFWSomsenGAPaulusWJ. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep. 2012;9:293-302.
38.
HammondJBalligandJL. Nitric oxide synthase and cyclic GMP signaling in cardiac myocytes: from contractility to remodeling. J Mol Cell Cardiol. 2012;52:330-340.
39.
KimHNJanuzziJL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015-2019.
40.
RitchieRHIrvineJCRosenkrantzAC. Exploiting cGMP based therapies for the prevention of left ventricular hypertrophy: NO and beyond. Pharmacol Ther. 2009;124:279-300.
41.
AbelEDLitwinSESweeneyG. Cardiac remodeling in obesity. Physiol Rev. 2008;88:389-419.
42.
Falcao-PiresILeite-MoreiraAF. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev. 2011;17:325-344.
43.
WittelesRMFowlerMB. Insulin resistant cardiomyopathy. J Am Coll Cardiol. 2008;51:93-102.
44.
KatoSSpinaleFGTanakaRJohnsonWCooperG4thZileMR. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic dysfunction. Am J Physiol. 1995;269(3 pt 2)H863-H868.
45.
WeberKTJanickiJSPickR. Myocardial fibrosis and pathologic hypertrophy in the rat with renovascular hypertension. Am J Cardiol. 1990;65(14):1G-7G.
BerenjiKDraznerMHRothermelBAHillJA. Does load-induced ventricular hypertrophy progress to systolic heart failure?Am J Physiol Heart Circ Physiol. 2005;289(1):H8-H16.
48.
DostalDEBakerKM. Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart: mediation by the AT 1 receptor. Am J Hypertens. 1992;5(5 pt 1):276-280.
49.
Van HeerebeekLHandaniNFalcao-PiresI. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830-839.
50.
FischerTHMaierLSSossallaS. The ryanodine receptor leak: how a tattered receptor plunges the failing heart into crisis. Heart Fail Rev. 2013;18:475-483.
51.
AlagiakrishnanKBanachMJonesLGDattaSAhmedAAronowWS. Update on diastolic heart failure or heart failure with preserved ejection fraction in older adults. Ann Med. 2013;45:37-50.
52.
BelardinelliLShryockJCFraserH. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006;92(suppl 4):iv6-iv14.
53.
SossallaSFluschnikNSchotolaH. Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res. 2010;107:1150-1161.
54.
HuntSAbrahamWTChinM. 2009 focused update incorporated into the ACC/AHA guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009;119:e391-e479.
55.
FonarowGCStoughWGAbrahamWT. Characteristics, treatments and outcomes of patients with preserved systolic function hospitalized for heart failure. J Am Coll Cardiol. 2007;50:768-777.
56.
ChengCNodaTNozawaTLittleW. Effect of heart failure on the mechanism of exercise induced augmentation of mitral valve flow. Circ Res. 1993;72:795-806.
57.
FiciFUraiDTayfunS. Left ventricular diastolic dysfunction in newly diagnosed untreated hypertensive patients. Blood Press. 2012;21:331-337.
58.
SohnDChaiILeeD. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol. 1997;30:474-480.
59.
MahmoodFJainandunsingJMatyalR. A practical approach to echocardiographic assessment of perioperative diastolic dysfunction. J Cardiothorac Vasc Anesth. 2012;25:1115-1123.
60.
McKiePMBurnettJC. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. Mayo Clin Proc. 2005;80:1029-1036.
61.
AmmarKAJacobsenSJMahoneyDW. Prevalence and prognostic significance of heart failure stages: application of the ACC/AHA heart failure staging criteria in the community. Circulation. 2007;115:1563-1570.
62.
YuCMSandersonJEShumIOL. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Eur Heart J. 1996;17:1694-1702.
63.
GonzálezALópezBQuerejetaRZubillagaEEcheverríaTDíezJ. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010;55:1418-1424.
64.
NegiSIJeongEMShukrullahIRaicuMDudleySCJr.Association of low plasma adiponectin with early diastolic dysfunction. Congest Heart Fail. 2012;18:187-191.
65.
LeongDPDePasqualeCGSelvanayagamJB. Heart failure with normal ejection fraction: the complimentary roles of echocardiography and CMR imaging. JACC Cardiovasc Imaging. 2010;3:409-420.
66.
MaceiraAMPrasadSKKhanMPennellDJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417-426.
67.
KudelkaAMTurnerDALiebsonPRMaciochJEWangJZBarronJT. Comparison of cine magnetic resonance imaging and Doppler echocardiography for evaluation of left ventricular diastolic dysfunction. Am J Cardiol. 1997;80:384-386.
68.
CavalcanteJLTamarappooBKHachamovitchR. Association of epicardial fat, hypertension, subclinical coronary artery disease, and metabolic syndrome with left ventricular diastolic dysfunction. Am J Cardiol. 2012;110:1793-1798.
69.
SauerAWilcoxJEAndreiACPassmanRGoldbergerJJShahSJ. Diastolic electromechanical coupling: association of the ECG T-peak to T-end interval with echocardiographic markers of diastolic dysfunction. Circ Arrhythm Electrophysiol. 2012;5:537-543.
70.
SolomonSDJanardhananRVermaA; Varsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet. 2007;369:2079-2087.
71.
YusufSPfefferMASwedbergK. Effects of candesartan in patients with heart failure and preserved left ventricular ejection fraction: the CHARM Preserved Trial. Lancet. 2003;362:771-781.
72.
ClelandJGFTenderaMAdamusJ. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345.
73.
KazikAWilczekKPolonskiL. Management of diastolic heart failure. Folia Cardiol Excerpta. 2010;5:188-195.
EdelmannFWachterRSchmidtAG. Effect of spironolactone on diastolic dysfunction and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781-791.
76.
FukutaHSaneDCBrucksSLittleWC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation. 2005;112:357-363.
77.
RedfieldMMBorlaugBALewisGD. Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial. Circ Heart Fail. 2012;5:653-659.
MaierLS. New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep. 2012;9:183-191.
80.
PagelPSGrossmanWHaeringJMWarltierDC. Left ventricular diastolic function in the normal and diseased heart. Anesthesiology. 1993;79:1104-1120.
81.
SarkarSGuhaBiswasRRupertE. Echocardiographic evaluation and comparison of the effects of isoflurane, sevoflurane, and desflurane, on left ventricular relaxation indices in patients with diastolic dysfunction. Ann Card Anaesth. 2010;13:130-137.
